Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Net Cash Flow (2020 - 2024)

Immuneering (IMRX) has 5 years of Net Cash Flow data on record, last reported at -$9.1 million in Q4 2024.

  • For Q4 2024, Net Cash Flow fell 4.94% year-over-year to -$9.1 million; the TTM value through Dec 2024 reached -$23.3 million, down 75.81%, while the annual FY2024 figure was -$23.3 million, 75.81% down from the prior year.
  • Net Cash Flow reached -$9.1 million in Q4 2024 per IMRX's latest filing, up from -$14.5 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $56.7 million in Q3 2021 and bottomed at -$36.0 million in Q3 2023.
  • Average Net Cash Flow over 5 years is $71503.9, with a median of -$5.0 million recorded in 2021.
  • Peak YoY movement for Net Cash Flow: soared 1723.38% in 2021, then plummeted 212.31% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at $31.5 million in 2020, then tumbled by 201.74% to -$32.0 million in 2021, then soared by 88.2% to -$3.8 million in 2022, then crashed by 128.37% to -$8.6 million in 2023, then dropped by 4.94% to -$9.1 million in 2024.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$9.1 million in Q4 2024, -$14.5 million in Q3 2024, and -$6.6 million in Q2 2024.